<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01830660</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-TPOP1</org_study_id>
    <nct_id>NCT01830660</nct_id>
  </id_info>
  <brief_title>A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of&#xD;
      increasing platelet count in animal and human. This study is designed in dose escalation&#xD;
      fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate safety and tolerability of Hetrombopag Olamine.&#xD;
&#xD;
        2. To investigate pharmacokinetics of Hetrombopag Olamine Under fasting conditions.&#xD;
&#xD;
        3. To obtain pharmacodynamics information of Hetrombopag Olamine on platelet count&#xD;
           elevation in healthy volunteers.&#xD;
&#xD;
        4. To determine preliminary regimen for phase II study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in platelet count above baseline(%)on Day1,3,5,8,10,12,15,17,19,22,25,28 after dosing</measure>
    <time_frame>up to 4 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite pharmacokinetic (PK) parameters of eltrombopag following a single dose of eltrombopag</measure>
    <time_frame>For 5 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vital signs</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical laboratory parameters</measure>
    <time_frame>up to 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>hetrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hetrombopag Olamine Tablets</intervention_name>
    <arm_group_label>hetrombopag</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject must be adequately informed of the nature and risks of the study, able to&#xD;
             understand the risks associated with the study, and are willing to provide written&#xD;
             informed consent prior to screening.&#xD;
&#xD;
          2. Must be a healthy male between the ages of 18 to 45 years, inclusive.&#xD;
&#xD;
          3. Must have a BMI between 19 to 28 kg/m2, inclusive and a total body weight â‰¥50 kg.&#xD;
&#xD;
          4. Platelet counts must be within the normal range.&#xD;
&#xD;
          5. Subjects must be free of any clinically significant disease based on medical history&#xD;
             and physical examination.&#xD;
&#xD;
          6. Clinical laboratory tests (complete blood count [CBC], blood chemistries, and&#xD;
             urinalysis) must be within the normal limits or clinically acceptable.&#xD;
&#xD;
          7. Must be nonsmokers, defined as not having smoked tobacco or used chewing tobacco or&#xD;
             nicotine.&#xD;
&#xD;
          8. Subjects of reproductive potential with partners who are women of childbearing&#xD;
             potential, will be instructed to, and must be willing to practice a highly effective&#xD;
             method of birth control for the duration of the study and continuing 6 months after&#xD;
             discontinuing treatment with the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of hypersensitivity to hetrombopag olamine or its components.&#xD;
&#xD;
          2. History or presence of significant cardiovascular deficient, pulmonary, hepatic,&#xD;
             gallbladder or biliary tract, renal, hematological, gastrointestinal, endocrine,&#xD;
             immunological, dermatological, neurological, or psychiatric disease, or any other&#xD;
             condition known to interfere with the absorption, distribution, metabolism, or&#xD;
             excretion of drugs.&#xD;
&#xD;
          3. History of deep vein thrombosis, or any other thromboembolic event.&#xD;
&#xD;
          4. History or presence of conditions that may place the subject at increased risk as&#xD;
             determined by the investigator.&#xD;
&#xD;
          5. History of thrombocytopenia or bleeding due to abnormal platelet number or function.&#xD;
&#xD;
          6. History of platelet clumping that prevents reliable measurement of platelet counts.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maozhi Liang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>West China Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West China Hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>December 25, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2013</study_first_posted>
  <last_update_submitted>April 3, 2015</last_update_submitted>
  <last_update_submitted_qc>April 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

